The short answer
Cyclosporine can raise potassium, so potassium supplements and potassium-containing salt substitutes need prescriber review. Potassium monitoring and individualized limits are supported, especially with kidney problems or an already high potassium level.
What this answer covers
Applies to oral or intravenous systemic cyclosporine, not eye drops; potassium content and other potassium-raising medicines matter.
- Supplement or preparation
- Potassium
- Medication ingredient
- cyclosporine
Evidence and practical considerations
Timing & monitoring
Exact systemic cyclosporine guidance advises limiting potassium intake and consulting before potassium-containing salt substitutes because cyclosporine can cause hyperkalemia; serum potassium is monitored. Adjudication lead: supported avoidance or limitation with clinician-directed exceptions. Animal, in-vitro, product, route, and formulation boundaries were applied without silent extrapolation.
- Exact scope
- potassium supplements or potassium-containing salt substitutes with cyclosporine
- Medication form and route
- systemic oral or intravenous cyclosporine; ophthalmic use excluded
- Timing or duration
- Potassium supplements and salt substitutes need clinician review throughout treatment, especially with renal dysfunction or hyperkalemia.
What remains uncertain
- Exact cyclosporine RxCUI 3008 IN is preserved; precise ingredients, salts, combinations, and other calcineurin inhibitors are not silently merged.
- Modified and nonmodified systemic finished products remain distinct unless the source explicitly bridges active moiety and formulation.
- Systemic evidence is not transferred to ophthalmic cyclosporine.
- Preclinical plausibility is not treated as a human clinical interaction; no conflicting_evidence decision is used without genuinely opposing exact endpoints.
Factors that may matter: baseline serum potassium; renal function; supplement or salt-substitute potassium content; ACE inhibitor, ARB, or potassium-sparing diuretic.
Read the supporting source summaries
Source 1: NIH patient drug guidance
medlineplus.gov · Source check Jul 25, 2026
Population: Patients taking oral cyclosporine or cyclosporine modified for transplant prevention, rheumatoid arthritis, or psoriasis.
Guidance says to avoid grapefruit, discuss potassium-rich foods and salt substitutes, disclose St. John's wort, and report low cholesterol, low magnesium, or high potassium.
Patient guidance supplies management instructions without comparative estimates, assay details, or evidence grading.
Source 2: clinical review or professional reference
mskcc.org · Source check Jul 25, 2026
Population: Adults taking systemic cyclosporine.
MSK directs users of these potassium-raising products to consult the prescriber.
No serum-potassium threshold, intake ceiling, or comparative risk estimate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Research summary published |
Article revision: e7289e8a09d0dac7
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.